Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.595 USD | -0.31% | -1.54% | +13.12% |
Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.12% | 109M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- LIFE Stock
- News aTyr Pharma, Inc.
- aTyr Pharma : Roth Capital Adjusts aTyr Pharma's Price Target to $21 from $20, Keeps Buy Rating